News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neumedicines Inc. Receives an Award of $8.3 Million From Biomedical Advanced Research and Development Authority (BARDA) for Continued Development of HemaMax as a Countermeasure to Acute Radiation Exposure


6/10/2013 10:03:12 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and as a hematological adjuvant cancer therapy (HACT), announces the award of $8.3 million from the Biomedical Advanced Research & Development Authority (BARDA) of the U.S. Department of Health and Human Services (DHHS) for the continued development of HemaMax™ (recombinant human interleukin 12 or rHuIL-12) for hematopoietic syndrome of acute radiation sickness (HSARS). This award is based on the exercise of Option 1 of the existing contract with BARDA for advanced development of HemaMax™.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES